Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0029503 (Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00492089Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerSupportive Care